lenalidomide has been researched along with prednisolone in 30 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (prednisolone) | Trials (prednisolone) | Recent Studies (post-2010) (prednisolone) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 34,414 | 3,302 | 7,141 |
| Protein | Taxonomy | lenalidomide (IC50) | prednisolone (IC50) |
|---|---|---|---|
| Glucocorticoid receptor | Homo sapiens (human) | 0.0278 | |
| Progesterone receptor | Homo sapiens (human) | 2.08 | |
| Glucocorticoid receptor | Rattus norvegicus (Norway rat) | 0.0565 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.016 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 0.0322 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 0.016 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.016 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (10.00) | 29.6817 |
| 2010's | 20 (66.67) | 24.3611 |
| 2020's | 7 (23.33) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Okamoto, S | 1 |
| Higa, GM; Saad, AA; Sharma, M | 1 |
| Ozaki, S | 1 |
| Allegra, A; Alonci, A; Catena, S; D'Angelo, A; Gerace, D; Greve, B; Musolino, C; Penna, G; Russo, S | 1 |
| Sucak, GT; Suyanı, E; Yağcı, M | 1 |
| Allegra, A; Alonci, A; Cannavò, A; D'Angelo, A; Musolino, C; Penna, G; Petrungaro, A; Romeo, G; Russo, S | 1 |
| Balducci, M; Chiusolo, P; De Stefano, V; Giannotta, C; Laurenti, L; Leone, G; Luigetti, M; Sabatelli, M; Sica, S; Sorà, F; Vannata, B | 1 |
| Suzuki, K | 1 |
| Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S | 1 |
| Al-Ali, HK; Beck, J; Edelmann, T; Hebenstreit, K; Heyn, S; Hoffmann, FA; Jäkel, N; Lange, T; Mohren, M; Niederwieser, D; Pönisch, W; Röhrborn, R; Schmalfeld, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T | 1 |
| Fuchida, S; Hino, M; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsumura, I; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Shimura, Y; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uoshima, N | 1 |
| Chen, CY; Chen, YC; Chou, SJ; Chou, WC; Hou, HA; Huang, SY; Lin, CW; Lin, HH; Lu, HY; Tang, JL; Tien, HF; Tsay, W; Wu, SJ; Yao, M | 1 |
| Caballero, D; Coiffier, B; d'Amore, F; Dearden, C; Federico, M; Gomes da Silva, M; Jäger, U; Morschhauser, F; Pettengell, R; Tilly, H; Trümper, L; Weidmann, E; Zinzani, PL; Zucca, E | 1 |
| Yamamoto, K | 1 |
| Akasaka, H; Ito, K; Kodaka, T; Sakane, E; Takahashi, T; Tsunemine, H; Yoshioka, S | 1 |
| Jain, N; Malhotra, P; Prakash, G; Sahu, KK; Saikia, U; Yanamandra, U | 1 |
| Rabinovich, CE; Schanberg, LE; Wershba, EC; Wu, EY | 1 |
| Fuchida, SI; Hatsuse, M; Murakami, S; Odaira, E; Okano, A; Shimazaki, C | 1 |
| Bakane, A; Balaji, R; Raj, R; Ramachandrakurup, S; Subburaj, D; Uppuluri, R | 1 |
| Andrea, M; Beck, J; Becker, C; Bill, M; Edelmann, T; Gläser, D; Heyn, S; Hoffmann, FA; Jentzsch, M; Kragl, B; Kreibich, U; Lange, T; Mohren, M; Mügge, LO; Niederwieser, D; Pönisch, W; Schliwa, T; Schwarzer, A; Schwind, S; Uhlig, J; Winkelmann, C; Zehrfeld, T | 1 |
| Auger-Quittet, S; Bareau, B; Belhadj-Merzoug, K; Benboubker, L; Bosson, JL; Boyle, E; Cliquennois, M; Decaux, O; Fuzibet, JG; Karlin, L; Leleu, X; Leyronnas, C; Orsini-Piocelle, F; Pegourie, B; Pernod, G; Rey, P; Rodon, P; Royer, B; Slama, B; Tiab, M; Voog, E; Zarnitsky, C | 1 |
| Brioli, A; Fabisch, C; Hänel, M; Hochhaus, A; Illmer, T; Knop, S; Krammer-Steiner, B; Manz, K; Mügge, LO; Pfirrmann, M; Prange-Krex, G; Schwarzer, AC; von Lilienfeld-Toal, M | 1 |
| Abe, Y; Fujita, H; Handa, H; Hayashi, T; Ishida, T; Kiguchi, T; Kimura, H; Kondo, S; Kosugi, H; Kubo, K; Mitani, K; Morita, S; Murakami, H; Ohashi, K; Ohta, K; Omoto, E; Ozaki, S; Sakai, R; Shimizu, K; Sunami, K; Takamatsu, H; Takezako, N; Yamamoto, S | 1 |
| Bradbury, CA; Cairns, DA; Child, JA; Cook, G; Craig, Z; Davies, FE; Drayson, MT; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Morgan, GJ; Owen, RG; Paterson, A; Pawlyn, C | 1 |
| Au-Yeung, R; Chan, TSY; Ip, AHW; Kwong, YL; Pang, AWK | 1 |
| Chen, Y; Cutter, D; Loh, Y; Master, Z; Mikhaeel, G; Nagarajan, C; Thitsar, SM; Tin, KM; Yeoh, KW | 1 |
| Ara, T; Fukuhara, O; Harigae, H; Ito, T; Katsuoka, Y; Kimura, T; Kobayashi, N; Minauchi, K; Nakajima, S; Noji, H; Onishi, Y; Ota, S; Sasaki, O; Yamamoto, J; Yokoyama, H | 1 |
| Iida, S; Inagaki, H; Ishida, T; Ito, A; Iwasaki, H; Kusumoto, S; Masaki, A; Murase, T; Muto, R; Nakano, N; Sakamoto, Y; Takeshita, M; Tashiro, Y; Tokunaga, M; Ueda, R; Utsunomiya, A; Yonekura, K | 1 |
10 review(s) available for lenalidomide and prednisolone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Recent progress in diagnosis of and therapy for multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide | 2006 |
Treatment of multiple myeloma in the targeted therapy era.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning | 2009 |
[New treatment strategies for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Diagnosis, Differential; Doxorubicin; Drug Discovery; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisolone; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide; Vincristine | 2009 |
Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Multiple Myeloma; Prednisolone; Stevens-Johnson Syndrome; Thalidomide | 2012 |
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Depsipeptides; Diphtheria Toxin; Doxorubicin; Folic Acid Antagonists; Histone Deacetylase Inhibitors; Humans; Immunoconjugates; Interleukin-2; Lenalidomide; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Peptides, Cyclic; Prednisolone; Recombinant Fusion Proteins; Stem Cell Transplantation; Thalidomide; Topoisomerase Inhibitors; Vincristine | 2014 |
[Standard of care and new drugs for diffuse large B-cell lymphoma].
Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Discovery; Epigenesis, Genetic; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Molecular Targeted Therapy; Piperidines; Prednisolone; Prednisone; Pyrazoles; Pyrimidines; Radiotherapy, Adjuvant; Rituximab; Thalidomide; Vincristine; Vindesine | 2014 |
[Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisolone; Recurrence; Thalidomide | 2015 |
Quincke's edema and hypersensitivity pneumonitis induced by lenalidomide for multiple myeloma.
Topics: Alveolitis, Extrinsic Allergic; Angioedema; Angiogenesis Inhibitors; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisolone; Thalidomide; Tomography, X-Ray Computed | 2016 |
7 trial(s) available for lenalidomide and prednisolone
| Article | Year |
|---|---|
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisolone; Recurrence; Thalidomide | 2013 |
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisolone; Prospective Studies; Thalidomide | 2017 |
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazoles; Pyridones; Thalidomide; Venous Thromboembolism | 2019 |
Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Double-Blind Method; Female; Frail Elderly; Frailty; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prednisolone; Progression-Free Survival | 2020 |
Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Survival Rate | 2020 |
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Incidence; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Progression-Free Survival; Risk Assessment; Thalidomide; Thrombophilia; Thrombosis; Transplantation, Autologous; Venous Thromboembolism; Vincristine | 2020 |
Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Febrile Neutropenia; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Progression-Free Survival; Remission Induction; Treatment Outcome; Young Adult | 2020 |
13 other study(ies) available for lenalidomide and prednisolone
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Complete remission with a combination of lenalidomide, cyclophosphamide and prednisolone in a patient with incomplete POEMS syndrome.
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Gait Disorders, Neurologic; Glucocorticoids; Hand Deformities, Acquired; Humans; Lenalidomide; POEMS Syndrome; Prednisolone; Proteasome Inhibitors; Remission Induction; Thalidomide; Vascular Endothelial Growth Factors | 2011 |
Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Dexamethasone; Drug Eruptions; Female; HLA-A Antigens; HLA-B Antigens; HLA-C Antigens; HLA-DQ beta-Chains; HLA-DRB1 Chains; Humans; Italy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisolone; Severity of Illness Index; Thalidomide; White People | 2012 |
Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Humans; Humerus; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Osteosclerosis; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Prednisolone; Recurrence; Salvage Therapy; Thalidomide; Transplantation, Autologous | 2012 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine | 2013 |
Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisolone; Prognosis; Pyrazines; Retreatment; Salvage Therapy; Thalidomide; Treatment Outcome | 2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Paraffin Embedding; Peptide Hydrolases; Prednisolone; Pyrazines; Salvage Therapy; Survival Analysis; Syndecan-1; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases | 2014 |
Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, AIDS-Related; Maxillary Sinus Neoplasms; Plasmablastic Lymphoma; Poverty; Prednisolone; Remission Induction; Thalidomide; Vincristine | 2016 |
Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.
Topics: Adolescent; Female; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Prednisolone; Retrospective Studies; Thalidomide; Treatment Outcome; Young Adult | 2017 |
Successful Treatment of Refractory Langerhans Cell Histiocytosis of the Choroid Plexus in a Child With Pulse Dexamethasone and Lenalidomide.
Topics: Choroid Plexus; Cladribine; Cytarabine; Dexamethasone; Diabetes Insipidus; Drug Resistance; Histiocytosis, Langerhans-Cell; Humans; Infant; Lenalidomide; Male; Pituitary Gland, Posterior; Prednisolone; Pulse Therapy, Drug; Remission Induction; Salvage Therapy; Skull Base; Thalidomide; Thoracic Vertebrae; Vinblastine | 2017 |
Unique evolution of angioimmunoblastic T cell lymphoma to Epstein-Barr virus-positive plasma cell myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Etoposide; Herpesvirus 4, Human; Humans; Lenalidomide; Lymphoma, T-Cell; Male; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisolone; Vincristine | 2020 |
Pleural plasmacytomas - the role of radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Fatal Outcome; Female; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Pleural Neoplasms; Prednisolone; Thalidomide | 2020 |
Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; CD28 Antigens; Cyclophosphamide; DNA Copy Number Variations; Doxorubicin; Etoposide; Female; Genes, p53; Hematopoietic Stem Cell Transplantation; Humans; INDEL Mutation; Kaplan-Meier Estimate; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Mutation; Nitrosourea Compounds; Polymorphism, Single Nucleotide; Prednisolone; Prednisone; Prognosis; Receptors, CCR4; Vincristine; Vindesine | 2021 |